China’s AI-driven health tech boom: How state-led biotech reshapes global equity and surveillance risks
Original framing: “China is excelling in health tech. That’s good news for the world” — Rest of World
The voices of Chinese dissidents, rural patients, and biotech factory workers are systematically excluded from narratives of 'health tech progress.' For instance, *Chen Qiushi*, a journalist who documented COVID-19 whistleblowing, reported that AI-driven contact tracing in Wuhan was used to target critics rather than contain the virus. Meanwhile, workers at *SenseTime* (a leading AI health firm) have described being forced to train facial recognition algorithms on medical imaging data without consent. Marginalized groups also include 'left-behind' elders in rural China, who are often denied access to AI diagnostics due to digital literacy barriers—yet their struggles are framed as 'user error,' not systemic design flaws. The power to define 'health tech excellence' lies with elites, while the costs are borne by those with the least agency.
China’s AI health tech boom is not an isolated triumph but a symptom of deeper systemic fractures: the global race to monetize human data, the erasure of Indigenous and marginalized knowledge, and the complicity of Western powers in enabling authoritarian tech ecosystems.
The narrative of 'excellence' obscures how this model replicates historical patterns of extraction—where innovation is framed as apolitical while the political (data sovereignty, labor rights, algorithmic bias) is treated as ancillary. Cross-cultural comparisons reveal that 'health tech' is not a universal good but a culturally contingent tool, with Indigenous and community-led systems often achieving better outcomes in contexts where trust and relational care matter more than efficiency metrics. The trickster reading exposes the hypocrisy: while the West condemns China’s surveillance state, it simultaneously collaborates with Chinese firms to outsource risky R&D, creating a false binary that masks shared responsibility. Solutions must move beyond tech-centric fixes to address the root causes—power imbalances in data governance, the militarization of health systems, and the need for decentralized, culturally adaptive alternatives. The path forward lies in restoring agency to marginalized communities, enforcing geopolitical ceasefires on high-risk biotech, and redefining 'excellence' to include ethical reciprocity, not just innovation speed.